子宫内膜样卵巢癌多中心真实世界队列的临床病理特征分析
基于法国ESME-Unicancer数据库2011至2016年多中心回顾性分析,共纳入3180例确诊为浆液性(2854例)或子宫内膜样(326例)卵巢癌患者。子宫内膜样患者更年轻、期别更早、分级更低、dMMR/MSI-high更常见,且Lynch综合征相关肿瘤家族史更多。中位随访51.7个月后,子宫内膜样亚组5年OS率为81%,浆液性亚组为55%(P<0.001);多因素分析显示子宫内膜样组织学类型与更好的OS(HR=0.38,95%CI[0.20-0.70],P=0.002)和PFS(HR=0.53,95%CI[0.37-0.75],P<0.001)独立相关。
要点
- 子宫内膜样卵巢癌患者更年轻、期别早、分级低,dMMR/MSI-high及Lynch综合征相关肿瘤史更常见。
- 子宫内膜样亚组5年OS率81%,显著优于浆液性亚组的55%(P<0.001)。
- 子宫内膜样组织学是OS和PFS的独立良好预后因素,提示需专门临床研究和管理。
核心结论
- 子宫内膜样与浆液性卵巢癌的诊断时临床病理特征不同,子宫内膜样组织学是独立的预后因素。
研究设计与样本
- 多中心回顾性分析,数据来自法国ESME-Unicancer卵巢癌数据库2011至2016年,共纳入3180例确诊为浆液性(2854例)或子宫内膜样(326例)卵巢癌患者。
主要发现
- 子宫内膜样患者更年轻、更多早期、低级别、dMMR/MSI-high,且更多个人/家族Lynch综合征相关肿瘤史;浆液性患者BRCA1/2突变更常见。
- 子宫内膜样患者接受化疗和贝伐珠单抗的比例更低。
- 中位随访51.7个月(95%CI[50.1-53.6]),5年OS率子宫内膜样亚组为81%(95%CI[74-85]),浆液性亚组为55%(95%CI[53-57]),P<0.001。
- 多因素分析(纳入年龄、ECOG-PS、FIGO分期、分级和组织学)显示,子宫内膜样亚型与更好的OS独立相关(HR=0.38,95%CI[0.20-0.70],P=0.002),与更好的PFS独立相关(HR=0.53,95%CI[0.37-0.75],P<0.001)。
临床怎么用
- 临床中应认识到子宫内膜样卵巢癌患者预后较好,可能避免过度治疗,但需结合个体情况。
- 对子宫内膜样卵巢癌患者应考虑dMMR/MSI检测及Lynch综合征评估。
- 子宫内膜样卵巢癌可能需要专门的临床试验和管理策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prognostic significance of endometrioid epithelial ovarian cancer (EOC) is controversial. We compared clinical, pathological, and biological features of patients with endometrioid and serous EOC, and assessed the independent effect of histology on outcomes. METHODS: We conducted a multicenter retrospective analysis of patients with EOC selected from the French Epidemiological Strategy and Medical Economics OC database between 2011 and 2016. Our main objective was to compare overall survival (OS) in endometrioid and serous tumors of all grades. Our second objectives were progression-free survival (PFS) and prognostic features. RESULTS: Out of 10,263 patients included, 3180 cases with a confirmed diagnosis of serous (N = 2854) or endometrioid (N = 326) EOC were selected. Patients with endometrioid histology were younger, more often diagnosed at an early stage, with lower-grade tumors, more frequently dMMR/MSI-high, and presented more personal/familial histories of Lynch syndrome-associated cancers. BRCA1/2 mutations were more frequently identified in the serous population. Endometrioid patients were less likely to receive chemotherapy, with less bevacizumab. After median follow-up of 51.7 months (95CI[50.1-53.6]), five-year OS rate was 81% (95CI[74-85]) in the endometrioid subgroup vs. 55% (95CI[53-57] in the serous subset (p < 0.001, log-rank test). In multivariate analyses including [age, ECOG-PS, FIGO, grade, and histology], the endometrioid subtype was independently associated with better OS (HR = 0.38, 95CI[0.20-0.70], p= 0.002) and PFS (HR = 0.53, 95CI[0.37-0.75], p < 0.001). CONCLUSIONS: Clinicopathological features at diagnosis are not the same for endometrioid and serous EOC. Endometrioid histology is an independent prognosis factor in EOC. These observations suggest the endometrioid population requires dedicated clinical trials and management.
引用
- De Nonneville A, Zemmour C, Frank S, et al. Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database. Gynecol Oncol. 2021. PMID: 34294414. doi:10.1016/j.ygyno.2021.07.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。